Art. -Nr.: HY-12954

PTACH

Name: PTACH
Brand: MedChemExpress
SKU: HY-12954
Price: 53.00 USD
Availability: InStock
Rating: 5 (1 reviews)

(Synonyms: NCH-51)

Kundenbewertung

Based on 1 Customer Validation

PTACH (NCH-51) is a potent HDAC inhibitor with IC₅₀s of 48 nM, 32 nM, and 41 nM for HDAC1, HDAC4, and HDAC6, respectively. PTACH exerts potent growth inhibition against various cancer cells (EC₅₀s of 1.1-9.1 μM) .

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 97.04%
CAS. Nr.: 848354-66-5
Formel: C₂₀H₂₆N₂O₂S₂
Molecular Weight:390.56

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

PTACH Chemical Structure

CAS. Nr.: 848354-66-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[2]

HDAC1

48 nM (IC₅₀)

HDAC4

32 nM (IC₅₀)

HDAC6

41 nM (IC₅₀)

HIV-1

Alle HDAC Isoform-spezifische Produkte anzeigen :

Alle HIV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A498	EC₅₀	6.8 μM Compound: NCH-51	Inhibition of A498 cell proliferation (mean) Inhibition of A498 cell proliferation (mean)	[PMID: 17257837]
DLD-1	EC₅₀	2.3 μM Compound: NCH-51	Inhibition of DLD-1 cell proliferation (mean) Inhibition of DLD-1 cell proliferation (mean)	[PMID: 17257837]
DU-145	EC₅₀	4.5 μM Compound: 51	Effective Concentration of compound to inhibit the growth of human DU-145 cells Effective Concentration of compound to inhibit the growth of human DU-145 cells	[PMID: 15715470]
DU-145	EC₅₀	4.5 μM Compound: 58	Inhibition of human DU145 cells Inhibition of human DU145 cells	[PMID: 18247554]
HCT-116	EC₅₀	1.3 μM Compound: NCH-51	Inhibition of HCT116 cell proliferation (mean) Inhibition of HCT116 cell proliferation (mean)	[PMID: 17257837]
HCT-116	EC₅₀	3 μM Compound: 51	Effective Concentration of compound to inhibit the growth of human HCT116 cells Effective Concentration of compound to inhibit the growth of human HCT116 cells	[PMID: 15715470]
HCT-116	EC₅₀	3 μM Compound: 58	Inhibition of human HCT116 cells Inhibition of human HCT116 cells	[PMID: 18247554]
LOX IMVI	EC₅₀	1.1 μM Compound: 51	Effective Concentration of compound to inhibit the growth of human LOX-IMVI cells Effective Concentration of compound to inhibit the growth of human LOX-IMVI cells	[PMID: 15715470]
LOX IMVI	EC₅₀	1.1 μM Compound: 58	Inhibition of human LOX-IMVI cells Inhibition of human LOX-IMVI cells	[PMID: 18247554]
Malme-3M	EC₅₀	4.3 μM Compound: NCH-51	Inhibition of MALME-3M cell proliferation (mean) Inhibition of MALME-3M cell proliferation (mean)	[PMID: 17257837]
MDA-MB-231	EC₅₀	2.3 μM Compound: 51	Effective Concentration of compound to inhibit the growth of human MDA-MB-231 cells Effective Concentration of compound to inhibit the growth of human MDA-MB-231 cells	[PMID: 15715470]
MDA-MB-231	EC₅₀	2.3 μM Compound: 58	Inhibition of human MDA-MB-231 cells Inhibition of human MDA-MB-231 cells	[PMID: 18247554]
MDA-MB-231	EC₅₀	4.4 μM Compound: NCH-51	Inhibition of MDA-MB-231 cell proliferation (mean of two experiments) Inhibition of MDA-MB-231 cell proliferation (mean of two experiments)	[PMID: 17257837]
NCI-H226	EC₅₀	2.6 μM Compound: 51	Effective Concentration of compound to inhibit the growth of human NCI-H226 cells Effective Concentration of compound to inhibit the growth of human NCI-H226 cells	[PMID: 15715470]
NCI-H226	EC₅₀	2.6 μM Compound: 58	Inhibition of human NCI-H226 cells Inhibition of human NCI-H226 cells	[PMID: 18247554]
NCI-H460	EC₅₀	2 μM Compound: 58	Inhibition of human NCI-H460 cells Inhibition of human NCI-H460 cells	[PMID: 18247554]
NCI-H460	EC₅₀	2.1 μM Compound: 51	Inhibition of human lung cancer NCI-H460 cell growth Inhibition of human lung cancer NCI-H460 cell growth	[PMID: 15715470]
NCI-H460	EC₅₀	2.1 μM Compound: NCH-51	Inhibition of NCI-H460 cell proliferation (mean) Inhibition of NCI-H460 cell proliferation (mean)	[PMID: 17257837]
PC-3	EC₅₀	9.5 μM Compound: NCH-51	Inhibition of PC-3 cell proliferation (mean) Inhibition of PC-3 cell proliferation (mean)	[PMID: 17257837]
SK-OV-3	EC₅₀	4.5 μM Compound: 51	Effective Concentration of compound to inhibit the growth of human SK-OV-3 cells Effective Concentration of compound to inhibit the growth of human SK-OV-3 cells	[PMID: 15715470]
SK-OV-3	EC₅₀	4.5 μM Compound: 58	Inhibition of human SKOV3 cells Inhibition of human SKOV3 cells	[PMID: 18247554]
SNB-78	EC₅₀	9.1 μM Compound: 51	Effective Concentration of compound to inhibit the growth of human SNB-78 cells Effective Concentration of compound to inhibit the growth of human SNB-78 cells	[PMID: 15715470]
SNB-78	EC₅₀	9.1 μM Compound: 58	Inhibition of human SNB78 cells Inhibition of human SNB78 cells	[PMID: 18247554]
St-4	EC₅₀	5 μM Compound: 51	Effective Concentration of compound to inhibit the growth of human St-4 cells Effective Concentration of compound to inhibit the growth of human St-4 cells	[PMID: 15715470]
St-4	EC₅₀	5 μM Compound: 58	Inhibition of human St4 cells Inhibition of human St4 cells	[PMID: 18247554]
T47D	EC₅₀	8.3 μM Compound: NCH-51	Inhibition of T-47D cell proliferation (mean of two experiments) Inhibition of T-47D cell proliferation (mean of two experiments)	[PMID: 17257837]

In Vitro

PTACH (compound 51) treatment elevates the levels of acetylated histone H4 and p21^WAF1/CIP1 in a dose-dependent manner^[1].
In cancer cell growth inhibition assay, PTACH (compound 51) shows strong activity. PTACH inhibits various cancer cells with EC50 values of 2.3 μM, 9.1 μM, 3.0 μM, 2.6 μM, 1.1 μM, 4.5 μM, 2.4 μM, 5.0 μM, and 4.5 μM for MDA-MB-231, SNB-78, HCT116, NCI-H226, LOX-IMVI, SK-OV-3, RXF-631L, St-4, and DU-145 cells, respectively^[1].
PTACH (NCH-51) augments the HIV-1 production in latently infected OM10.1 cells and such reactivation is associated with a loss of HDAC1 occupancy and subsequent hyperacetylation of histones in nuc-1 at the HIV-1 promoter^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HCT 116 cells
Concentration:

1 μM, 5 μM, 25 μM
Incubation Time:

8 hours
Result:

Gave rise to elevated and dose-dependent levels of acetylated histone H4 and p21^WAF1/CIP1.

Chemical Information

CAS. Nr. 848354-66-5
Appearance Solid
Molecular Weight 390.56
Formel C₂₀H₂₆N₂O₂S₂
Color White to off-white
SMILES

CC(C)C(SCCCCCCC(NC1=NC(C2=CC=CC=C2)=CS1)=O)=O
Synonyms

NCH-51
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (128.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5604 mL

12.8021 mL

25.6043 mL

5 mM

0.5121 mL

2.5604 mL

5.1209 mL

10 mM

0.2560 mL

1.2802 mL

2.5604 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (476 KB)
- English - EN (476 KB)
- Français - FR (476 KB)
- Deutsch - DE (476 KB)
- Norwegian - NO (476 KB)
- Español - ES (476 KB)
- Swedish - SV (476 KB)
- Italian - IT (476 KB)
- Korean - KR (476 KB)
- Portuguese - PT (476 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Suzuki T, et al. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem. 2005 Feb 24;48(4):1019-1032. [Content Brief]

[2]. Ann Florence B Victoriano, et al. Novel histone deacetylase inhibitor NCH-51 activates latent HIV-1 gene expression. FEBS Lett. 2011 Apr 6;585(7):1103-11. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5604 mL	12.8021 mL	25.6043 mL	64.0107 mL
	5 mM	0.5121 mL	2.5604 mL	5.1209 mL	12.8021 mL
	10 mM	0.2560 mL	1.2802 mL	2.5604 mL	6.4011 mL
	15 mM	0.1707 mL	0.8535 mL	1.7070 mL	4.2674 mL
	20 mM	0.1280 mL	0.6401 mL	1.2802 mL	3.2005 mL
	25 mM	0.1024 mL	0.5121 mL	1.0242 mL	2.5604 mL
	30 mM	0.0853 mL	0.4267 mL	0.8535 mL	2.1337 mL
	40 mM	0.0640 mL	0.3201 mL	0.6401 mL	1.6003 mL
	50 mM	0.0512 mL	0.2560 mL	0.5121 mL	1.2802 mL
	60 mM	0.0427 mL	0.2134 mL	0.4267 mL	1.0668 mL
	80 mM	0.0320 mL	0.1600 mL	0.3201 mL	0.8001 mL
	100 mM	0.0256 mL	0.1280 mL	0.2560 mL	0.6401 mL

Bioz

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PTACH

LMK-235

Nexturastat A

SR-4370

Trichostatin A

BML-210

Tubacin

ACY-738

Scriptaid

NKL 22

Sodium 4-phenylbutyrate

Suberoyl bis-hydroxamic acid

Vorinostat

Alle HDAC Isoform-spezifische Produkte anzeigen

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

PTACH

LMK-235

Nexturastat A

SR-4370

Trichostatin A

BML-210

Tubacin

ACY-738

Scriptaid

NKL 22

Sodium 4-phenylbutyrate

Suberoyl bis-hydroxamic acid

Vorinostat

Alle HDAC Isoform-spezifische Produkte anzeigen

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

PTACH Related Classifications

HY-12954 Related Classifications

Bioz